Humberto Reynales - Concepedia

Author

Humberto Reynales

Research Institute for Tropical Medicine ORCID

Also Known As

Ernesto Aycardi, H. Reynales, Hector Velásquez, Humberto Reynales, Humberto Reynales Londoño, María José Reyes Fentanes

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Research Institute for Tropical Medicine Mahidol University Takeda (Switzerland)Universidad del Valle Mahidol Oxford Tropical Medicine Research Unit

About

Humberto Reynales is an author at Research Institute for Tropical Medicine specializing in vaccine safety, vaccination, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	602
2	Immunology	5	5	319
3	Epidemiology	2	2	70
4	Public Health	1	1	46
5	Humoral Immunity	1	1	24

Humberto Reynales

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease Sri Rezeki Hadinegoro, José Luis Arredondo-Garcı́a, Maria Rosario Capeding, New England Journal of Medicine	2015	1.1K
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America Luis Villar, Gustavo H. Dayan, José Luis Arredondo-Garcı́a, New England Journal of Medicine	2014	934
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents Shibadas Biswal, Humberto Reynales, Xavier Sáez‐Llorens, New England Journal of Medicine	2019	357
Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas, The Lancet VaccinationVaccine SafetyPediatricsVaccine TrialVaccine Efficacy	2020	237
Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003) Luis Rivera, Shibadas Biswal, Xavier Sáez‐Llorens, Clinical Infectious Diseases	2021	226
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial Vianney Tricou, Delia Yu, Humberto Reynales, The Lancet Global Health	2024	189
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri, The Lancet Infectious Diseases	2021	170
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects Sharon E. Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, Vaccine VaccinologyVaccine SafetyVaccinationCross-protectionVaccine Development	2014	136
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial Lulu Bravo, Igor Smolenov, Htay Htay Han, The Lancet VaccinologyVaccine SafetyVaccinationVaccine DevelopmentImmunology	2022	112
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination Eduardo López‐Medina, Shibadas Biswal, Xavier Sáez‐Llorens, The Journal of Infectious Diseases	2020	102

Page 1